Demand for external support driving growth of EQA

Demand for external support driving growth of EQA

“In Vitro Diagnostics (IVD) Quality Controls Market” recently published by Markets and Markets has highlighted an overall significant growth within the Quality Control Market. Further growth is anticipated in the coming years with the Markets and Markets report estimating that the IVD QC market will be worth $979 million.

One area that is currently experiencing growth within this sector is the EQA segment, which Markets and Markets estimates to command a 6.6% share of the overall IVD market. The report is crediting growth within this segment to you, the customer, stating “…various end users or customers of IVD quality control products mostly prefer external support to run their quality control activities. For this, market players are largely focusing on providing external quality assurance (EQA) support”. As such companies such as Randox are being approached to provide EQA for a range of small, independent laboratories and large laboratory chains alike.

What other factors have contributed to this growth?

The adoption of ISO15189 and other similar standards is becoming mandatory in many countries, as discussed in a previous blog post. Accreditation highlights the accuracy and reliability of the patient results being released. ISO15189 states that “The laboratory shall participate in interlaboratory comparisons such as those organised by external quality assessment or proficiency testing schemes”. Therefore laboratory managers are employing EQA programmes in their laboratory to meet such requirements. EQA also enables laboratories to meet other accreditation requirements such as peer comparison and clinically relevant testing.

Selecting the right EQA for you

When selecting the right EQA scheme for your laboratory there are a number of considerations to be made; sample frequency, peer group numbers, report format, report turnaround and so on. According to a survey conducted by Randox Quality Control 55% of respondents listed sample frequency as the most important feature to be considered when selecting an EQA scheme. Sample frequency is an ongoing debate regarding EQA. However, schemes with frequent reporting will allow you to easily pinpoint when an error occurred and implement corrective actions with minimal disruption. Also making the top three key factors in this survey were; quality samples and peer group numbers.

What can Randox Quality Control offer?

As the largest international EQA scheme available on the market RIQAS offers laboratories around the world assurance that the results they are releasing are accurate and reliable. With more than 40,000 participant in 124 countries and 32 flexible programmes we are certain that the external support we offer for your quality control activities will provide you with the upmost confidence in your laboratory’s performance. Furthermore with our programmes accepted by national and international accreditation bodies worldwide employing RIQAS can help you gain accredited status providing your end users with peace of mind. With other benefits such as programme consolidation, rapid report turnaround, easy to read at-a-glance reporting and the ability to register up to 5 instruments per programme at no extra cost why don’t you contact us today and find out how we can support your quality control activity?  

To request a visit from a QC consultant contact us via

Randox Celebrates Success at Global Sales Conference in Templepatrick

Randox employees gathered at the Hilton Hotel in Templepatrick from 4th to 8th of July for their Global Sales Conference. The conference was aimed at celebrating the hard work and dedication of Randox employees in addition to providing a chance for team building and enhanced product training. The week was a great success with critical sales information being discussed on existing products but also on exciting new products set to launch later this year. Through these product focused workshops and interactive sessions (including case studies and market success stories) the company is sure to benefit from the experience!

Inclusive of 130 Randox sales representatives from across 23 different countries, the sales conference was a multi-cultural experience with employees from the UK and Ireland, USA, Australia, China, France, Mexico, Brazil, Jamaica, the UAE, India, Puerto Rico, South Africa and Vietnam. To mark the diversity of the Randox team a series of presentations were given in the native language of Randox’s international employees; this really highlighted the global presence of Randox and enhanced the pride of Randox staff. This was further heightened by Dr Peter FitzGerald’s announcement of Randox hitting £1 billion of sales since inception.

Pride wasn’t the only factor adding to the motivation of Randox employees during the week. With the conference consisting of team briefings, training sessions and team building activities, Randox employees were boosted with a sense of support. These sessions focused on increasing their knowledge of current products, in addition to providing insight into new products which are soon to be released.

Speaking about these sessions, Global Marketing Manager, Eamon Lenehan said;

“It was fantastic to see so many of our sales teams, from across the world, in one place. It really highlighted the scale and reach of our business as a global company. The interactive sessions nurtured a sense of teamwork and debate across all product groups. The focus on unique selling points and key sales strategies for existing and exciting new products will enable our sales teams to reach and exceed their goals.”

Following this Global Marketing Manager, Stuart Penrose said;

“The interactive nature of our sessions really sang through; the main one being a “Master Mind” session that had a Magnus and 5 sales reps on the panels, all answering multiple choice questions and generating great debate amongst the team.”

All Randox divisions made an appearance from the Reagents, Quality Control and RX series clinical product divisions to Randox Biosciences, Food Diagnostics, Testing Services and Toxicology teams. To end the eventful week Randox employees were treated to a Gala dinner which was thoroughly enjoyed by all!

What is Visceral Fat?

Visceral fat (or abdominal fat) is body fat which is stored within the abdominal cavity. It wraps around your vital organs including the liver, pancreas and intestines, and as a result can have a negative impact on your health. In fact, visceral fat has been linked to increased risk of health problems such as type 2 diabetes, heart disease and some cancers.

It is important to distinguish the difference between subcutaneous fat and visceral fat…

Subcutaneous fat is the fat we store under our skin. It is the tissue that we can feel when we pinch ourselves, and contains blood vessels in addition to fatty tissues. Visceral fat, on the other hand, cannot be felt in such a way as it is the extra fat stored around our organs. It is the most dangerous type of fat as it much harder to identify.

No matter what your shape or size, you may be carrying excess visceral fat!

Regardless of shape or size an individual can be carrying excess visceral fat. This means that whether your doctor tells you that you’re underweight, overweight, obese or of a healthy weight, you may be carrying excess visceral fat within your abdominal cavity.

That is why BMI is an inaccurate measurement of health…

Body Mass Index (BMI) is used by many as an indicator of health. It involves comparing your weight in relation to your height to give an indication of your weight status i.e. whether you are categorised as underweight, overweight, healthy or obese. It doesn’t take into account muscle mass, age, sex, ethnicity, general level of fitness or visceral fat. Therefore, even if you have a ‘healthy’ BMI you may still be carrying excessive visceral fat, and could still be at risk of the health complications associated with it.

As a result, relying on BMI could put you at risk of countless diseases…

Visceral fat is often referred to as ‘active fat’ due to the effect it has on our hormones and body functions. It can interrupt normal hormone communications between your vital organs, and can lead to insulin resistance and eventually type 2 diabetes. Additionally, it can affect the functions of your organs and puts you at higher risk of developing heart disease or cancers including breast cancer or colorectal cancer.

So, what can you do to protect yourself?

Factors which contribute to visceral fat levels include stress, diet and exercise habits in addition to age, ethnicity and gender. Living a healthy lifestyle will therefore reduce your chances of visceral fat accumulating in your abdominal cavity.

If you are worried about your visceral fat levels the waist-to-hip ratio (found by dividing waist width by hip width) can give an indication of total fat as well as the level of visceral fat, however the most accurate measurement of visceral fat is to measure adiponectin levels in the blood.

Adiponectin (a blood analyte) is closely linked with visceral fat; low levels of adiponectin indicate high levels of visceral fat. The Adiponectin test enables true measurement of visceral fat levels and allows for more accurate measurement of health than traditional BMI; if you have been diagnosed with unhealthy BMI and believe this to be an inaccurate diagnosis, testing your adiponectin levels can help determine your true measurement of health. Simply ask your doctor for the Adiponectin test!

For health professionals:

The adiponectin test from Randox can accurately assess levels of abdominal visceral fat, independent of age, race or fitness level.  Assessing adiponectin, and therefore visceral fat levels, can help assess risk of CKD, as well as a range of other illnesses such as pre-diabetes, CVD and various cancers.  Contact us now for further information.

Randox diagnosed with success after hitting £1 billion of sales since inception

Randox Laboratories has made an impressive business announcement this week – from inception in 1982 the global healthcare company has now surpassed £1 billion of total sales in medical diagnostic products.

Founded by Dr. Peter FitzGerald just outside Crumlin, Co Antrim, Randox sold its first ever diagnostic blood test to Aberystwyth University Hospital.  Thirty four years later and the company has just made its billionth pound sale – highly innovative Respiratory Infection Biochips which test for multiple respiratory infections to quickly identify the most appropriate treatment – to a client in Saudia Arabia.  This technology, which is unique to Randox, not only improves antibiotic prescribing, but reduces the risk of growing antimicrobial resistance – a major global healthcare threat.

The major sales announcement was made at the company’s Global Sales Conference, being held this week in the Hilton Hotel, Templepatrick.

At this event, around 130 Randox sales representatives from across 23 different countries, including the UK and Ireland, the USA, Australia, China, France, Mexico, Brazil, Jamaica, the UAE, India, Puerto Rico, South Africa and Vietnam are gathered together in Randox’s native Northern Ireland for this notable milestone in the company’s history.

With briefings, team building and training on both current products and new capabilities about to be launched, the aim of the conference is to equip staff to increase the rate of company growth.  The conference will not only focus on product groups that advance human healthcare, such as Randox Reagents, Quality Control, Biosciences, and the RX Series Clinical Chemistry Analysers, but will also include Randox’s growing Food Diagnostics, Testing Services and Toxicology divisions.

Dr. Peter FitzGerald, Founder and Managing Director of Randox Laboratories, explained the company’s plans following the £1 billion sales announcement;

“Whilst we have clearly made our mark on the global diagnostics sector, there is much more that we want to do, to save and improve lives globally.   As such, once operational and infrastructure costs have been met, Randox reinvests all profits into further research and development and, as a result, we have more new tests in development than any other healthcare company in the world. This commitment to R&D has seen the successful development and expansion of Randox patented Biochip Array Technology – greatly improving the diagnosis of a wide range of conditions.  For example, we are currently working on the early and accurate diagnosis of a range of cancers, cardiovascular disease and Alzheimer’s disease. Our Randox Health clinics also allow newly validated tests to make a clinical impact more quickly than would normally be achieved through routine healthcare procurement processes. Whilst there is still much to be done in this area, with our first class people, our commitment to innovation and the world class facilities we are developing at the Randox Science Park in Antrim, in Dungloe in Co Donegal, in Bangalore in India and in West Virginia in the US, we are confident that we will continue to bring our cutting-edge diagnostics to more and more people across the globe.”

Clinical Laboratory Survey